DICE Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
DICE Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2022.
  • DICE Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$39.5M, a 81.6% decline year-over-year.
  • DICE Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2023 was -$119M, a 62.7% decline year-over-year.
  • DICE Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$88.2M, a 85.3% decline from 2021.
  • DICE Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$47.6M, a 101% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$88.2M -$40.6M -85.3% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-15
2021 -$47.6M -$23.9M -101% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$23.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.